. . . . . . . "[Eligible patients with HER2-negative clinical stage IIB-IIIC breast cancer received 12 weekly doses of paclitaxel (80�mg/m(2)) followed by AC (60/600�mg/m(2) every 2�weeks and filgrastim), plus T (100 or 200�mg PO on days 1-3 of each P dose, and 200�mg PO on days 2-7 of each AC cycle).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:47+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .